Targeted radiation therapy for advanced prostate cancer that is progressing

Plain-English translation of NCT07038304 on ClinicalTrials.gov ↗ · Source last updated June 2025 · Translation generated July 2026 · How we translate trials

What is this trial?

This trial is testing whether adding metastasis-directed radiotherapy (MDRT)—a type of focused radiation aimed directly at visible tumors—to your current prostate cancer treatment can help slow disease progression. You would be a good candidate if you have castration-resistant prostate cancer that is starting to progress (with 1 to 3 new or growing tumors detected on a special scan called PSMA PET) and you're already being treated with hormone therapy or other systemic treatments. The goal is to see if this treatment can delay the need to switch to stronger systemic therapies.

For patients with advanced prostate cancer that has become resistant to hormone therapy, progression often means switching to more intensive systemic treatments, which come with more side effects and costs. This trial exists to find out whether targeting the specific spots where cancer is progressing with radiation can buy you more time on your current treatment and improve how long you stay without further disease progression.

Do you qualify?

You likely qualify if…

you have been diagnosed with adenocarcinoma of the prostate
you have castration-resistant metastatic prostate cancer (testosterone levels below 50 ng/dL) and are currently on hormone therapy, possibly combined with chemotherapy or other systemic treatment
imaging (PSMA PET scan) shows you have oligoprogressive disease—meaning 1 to 3 new or growing metastases and/or a local recurrence in the prostate bed
you have completed or stopped chemotherapy (if you received it), or have shown response to other systemic treatments for at least 3 months
you are in good enough health to receive radiotherapy (WHO performance status 0–2) and are 18 years or older

You likely don't qualify if…

you have testosterone levels above 50 ng/dL (meaning your cancer is not yet castration-resistant)
you have more than 3 progressive metastases or new lesions
you have a local recurrence in the prostate bed that was previously treated with radiation
you have another active cancer (other than non-melanoma skin cancer) that could interfere with the trial results
you have comorbidities or previous treatments that would make it unsafe or impossible to receive this radiotherapy

What participation looks like

You would continue your current hormone or systemic therapy and receive focused radiation therapy (SBRT) targeted at the 1 to 3 tumors or areas where your cancer is progressing, as seen on your PSMA PET scan. The radiation is delivered over a few sessions (exact number depends on the location and size of your tumors). Throughout the trial, you would have regular follow-up appointments with imaging scans to track whether the treatment has delayed the need to switch to a stronger systemic therapy and has improved your progression-free survival.

Targeted radiation therapy for advanced prostate cancer that is progressing

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)